Improve yields and stress tolerance with ATI.
Our business model involves co-development or licensing. Preferred partners are innovative seed companies who are dissatisfied with current approaches to yield improvement, biotic and abiotic stress tolerance or extended shelf life.
Revenues achieved through:
ATI or its parent owns elite germplasm for improving yield, stress tolerance and/or shelf life, and introduces the improved varieties or hybrid parents directly into the marketplace.
Co-funding research, then sharing income on trait added value from sales of yield-enhanced, stress-tolerant seeds, and longer shelf life crops
Upfront technology & research maintenance fees
Benchmark payments for proof of concept / commercial development
Recurring revenues from trailing royalties on commercialized products
We boast a significant competitive advantage with domain technical, licensing and co-development experience, have dominant IP in plant yield genes with 16 issued US patents and foreign counterparts, and new applications for genome editing of our validated targets.
We are not aware of any direct competitors expressing commercially relevant yield genes in transgenic or genome edited plants with similar field trial data.
Most importantly, there are convincing laboratory, greenhouse and field trial demonstrations of broad applications to significantly improving crop yields with our technology, as well as secondary benefits in abiotic stress resistance, disease tolerance, and improved shelf life.
Co-development & licensing terms are negotiated by crop.
We seek co-development opportunities and licensees with innovative seed companies in alfalfa, banana, beans, cannabis, canola, corn, cotton, flowers, grapes, lettuce, okra, peanut, peas, rice, sorghum, sugarbeet, wheat and other crops.
For crop-specific Co-Development, we share research costs and can arrange:
Lab / Greenhouse / Field Testing / Regulatory Services
Upon success, we share added Net Trait Value on sales of seeds producing crops with yield-enhancement, stress-tolerance and/or long shelf-life.
For Licensing, we seek:
Technology Access & Research Maintenance Fees
Royalties on product sales
Criteria for target crop selection for genome editing:
Fully sequenced genome of a reference variety in the target species; and
Genetic transformation protocol with routine tissue culture permitting high efficiency plant transformation.
Licensing and Co-development terms are negotiated by crop.
With wide farmer adoption of genetically engineered crop plants, 457 million acres of all croplands have been planted to GM varieties in 26 countries (2016). In the US, over 93% of soy, cotton and corn are genetically modified. Additionally, over 18 million farmers in developing countries are growing 54% of worldwide GM crops. Over 20 major crop plants have been genetically engineered with improved traits, boosting worldwide commercial sales to exceed $15.7 Billion.
Agribody's genome editing via small and targeted mutations, with no foreign DNA in the final crop, avoids concerns associated with transgenics, which significantly reduces risk & costs, and speeds up commercialization.
Serviceable Available Market: $13 Bil.
Simply increasing alfalfa yields by 20% can boost seed value at a minimum of $50 Mil per year